OR WAIT null SECS
March 26, 2018
Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.
The agreement gives IncoCell Tianjin, a wholly-owned subsidiary of China-based Boyalife Group, access to Cesca’s celluar processing contract development and manufacturing services.
March 23, 2018
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
March 22, 2018
Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.
March 19, 2018
Emerson will provide Ireland’s National Institute of Bioprocessing Research and Training with technologies to help the institute prepare students for the transition to manufacturing digitization in the biopharmaceutical industry.
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
March 13, 2018
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
March 08, 2018
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.
March 06, 2018
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.